Cargando…

Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function

OBJECTIVE: The aim of this study was to determine the efficacy of sustained-release fampridine (4-aminopyridine) in veterans with multiple sclerosis (MS) with limited ambulatory ability, and its impact on motor function in an outpatient setting. DESIGN: Retrospective. SETTING: Tertiary referral cent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rabadi, Meheroz H., Kreymborg, Kimberly, Vincent, Andrea S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2013
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784065/ https://www.ncbi.nlm.nih.gov/pubmed/23873597 http://dx.doi.org/10.1007/s40268-013-0020-x

Ejemplares similares

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
por: Keune, Philipp M., et al.
Publicado: (2015)

The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis
por: Rabadi, Meheroz H, et al.
Publicado: (2021)

Impact of Adherence with Disease-Modifying Therapies on All-Cause Mortality Rates Among Veterans with Multiple Sclerosis
por: Rabadi, Meheroz H., et al.
Publicado: (2022)

Fampridine and quality of life in individuals with multiple sclerosis
por: Sagawa, Yoshimasa, et al.
Publicado: (2016)

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis
por: Zeller, D, et al.
Publicado: (2014)

Effect of Chronic Medical Conditions in Veterans with Multiple Sclerosis on Long-Term Disability
por: Rabadi, Meheroz H., et al.
Publicado: (2016)

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
por: Albrecht, Philipp, et al.
Publicado: (2018)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study
por: Mamoei, Sepehr, et al.
Publicado: (2021)

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
por: Hupperts, Raymond, et al.
Publicado: (2022)

Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients
por: Moghadasi, Abdorreza Naser
Publicado: (2021)

Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Health status profile and health-related quality of life of veterans attending an out-patient clinic
por: Rabadi, Meheroz H., et al.
Publicado: (2013)

Factors Predictive of Type of Powered Mobility Received by Veterans with Disability
por: Rabadi, Meheroz H., et al.
Publicado: (2015)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study
por: Mitsikostas, Dimos D., et al.
Publicado: (2021)

Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment
por: Ahdab, Rechdi, et al.
Publicado: (2019)

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
por: Hupperts, Raymond, et al.
Publicado: (2016)

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
por: Sola-Valls, Núria, et al.
Publicado: (2018)

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report
por: Müller, Mona Klara Ros, et al.
Publicado: (2022)

Efficacy and safety of short-term use of COX-2 inhibitors in patients after an acute stroke with musculoskeletal pain
por: Rabadi, Meheroz H., et al.
Publicado: (2013)

Review of the randomized clinical stroke rehabilitation trials in 2009
por: Rabadi, Meheroz H.
Publicado: (2011)

Progressive lip numbness due to numb chin and cheek syndrome in a patient with prostate cancer
por: Rabadi, Meheroz H.
Publicado: (2020)

Psoas muscle hematoma presenting as painful monoplegia
por: Rabadi, Meheroz H.
Publicado: (2020)

Fever in a paraplegia patient with a pressure ulcer
por: Rabadi, Meheroz H.
Publicado: (2021)

Patient with basilar artery occlusion related to metastatic melanoma
por: Rabadi, Meheroz H.
Publicado: (2023)

Corrigendum to “Fever in a paraplegia patient with a pressure ulcer” [Radiology Case Reports 16 (2021) 2434–2436]
por: Rabadi, Meheroz H.
Publicado: (2023)

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial
por: Kanhai, Kawita M. S., et al.
Publicado: (2019)

Prolonged-Release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: A Pilot, Double-Blind, Randomized, Placebo-Controlled Study
por: Jacques, François, et al.
Publicado: (2018)

Effect of vitamin C supplementation on stroke recovery: A case-control study
por: Rabadi, Meheroz H, et al.
Publicado: (2007)

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
por: Hobart, Jeremy, et al.
Publicado: (2018)

Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
por: Castelnovo, Giovanni, et al.
Publicado: (2021)

Randomized Clinical Stroke Trials in 2007
por: Rabadi, Meheroz H, et al.
Publicado: (2008)

Neuroprotective Properties of 4-Aminopyridine
por: Dietrich, Michael, et al.
Publicado: (2021)

Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose
por: Ballesta Méndez, Maria, et al.
Publicado: (2014)

Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases
por: Prugger, Michael, et al.
Publicado: (2013)

The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic Drugs
por: Heuzeroth, Hanno, et al.
Publicado: (2019)

Aminopyridine block of transient potassium current
Publicado: (1982)

2-Aminopyridin-3-ol
por: Betz, Richard, et al.
Publicado: (2011)

Motor Alterations Induced by Chronic 4-Aminopyridine Infusion in the Spinal Cord In vivo: Role of Glutamate and GABA Receptors
por: Lazo-Gómez, Rafael, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3h5al83kt4op8dlkhqkt6u32bb